The Saudi Food and Drug Authority (SFDA) held a high-level meeting in Riyadh with directors of pharmaceutical services from public and private health authorities to improve drug safety monitoring and reporting.

Key highlights:

  • Led by Dr. Adel Al-Harf, the discussion focused on strengthening adverse event reporting and compliance with risk-reduction measures
  • Participants explored improved mechanisms for tracking drug quality and safety across healthcare settings
  • he initiative aligns with Vision 2030’s Health Sector Transformation Program, reinforcing national commitment to medicine safety and system-wide Regulatory improvement
     

Consult Now

Source
https://www.sfda.gov.sa/ar/news/4995502
Select Mandate HA
SFDA
Select Mandate Function
Regulatory Affairs